<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>GLAXO</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">GLAXO</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="glaxosmithkline-pharmaceuticals-limited" class="section level1">
<h1>GlaxoSmithKline Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAXO.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="glaxo-glaxosmithkline-pharmaceuticals-limited-investment-analysis-summary" class="section level9">
<p class="heading"><strong>GLAXO (GlaxoSmithKline Pharmaceuticals Limited) ‚Äì Investment Analysis Summary</strong></p>
<p><em>(As of November 6, 2025 ‚Äì Q2 FY2026 Financial and Strategic Review)</em></p>
<p>This analysis is based on GSK‚Äôs Unaudited Standalone &amp; Consolidated Financial Results for Q2 and H1 FY2026 (ending September 30, 2025), auditor reports, board disclosures, management commentary, and the Q2 Earnings Conference Call.</p>
<hr />
</div>
<div id="key-financial-highlights-q2-h1-fy26" class="section level6">
<h6>üîç <strong>1. Key Financial Highlights (Q2 &amp; H1 FY26)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Value (Q2)</th>
<th>Value (6 Months)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue (Operations)</strong></td>
<td>‚Çπ973.6 crores</td>
<td>‚Çπ1,778.5 crores</td>
</tr>
<tr class="even">
<td><strong>Standalone PAT</strong></td>
<td>‚Çπ255 crores</td>
<td>‚Çπ459.7 crores</td>
</tr>
<tr class="odd">
<td><strong>Consolidated Revenue (Operations)</strong></td>
<td>‚Çπ979.9 crores</td>
<td>‚Çπ1,785.1 crores</td>
</tr>
<tr class="even">
<td><strong>Consolidated PAT</strong></td>
<td>‚Çπ257.5 crores</td>
<td>‚Çπ462.5 crores</td>
</tr>
<tr class="odd">
<td><strong>EPS (Basic &amp; Diluted)</strong></td>
<td>‚Çπ15.06</td>
<td>‚Çπ27.14 (6M)</td>
</tr>
<tr class="even">
<td><strong>EBITDA Margin</strong></td>
<td><strong>34.4%</strong></td>
<td>‚Äî</td>
</tr>
<tr class="odd">
<td><strong>Dividend Paid</strong></td>
<td>‚Çπ714 crores</td>
<td>(H1 total)</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Top-line Decline:</strong> Revenue down <strong>2.6% YoY in Q2</strong>, primarily due to one-off headwinds.</li>
<li><strong>Profitability Improvement:</strong> Strong <strong>250bps YOY expansion in EBITDA margin</strong>, driven by cost optimization and mix shift.</li>
<li><strong>Cash Flow:</strong> Negative <strong>‚Çπ1.99 lakh crore net cash flow</strong> in H1, largely driven by significant <strong>dividend payout of ‚Çπ714 crores</strong>.</li>
<li><strong>Liquidity:</strong> Cash &amp; equivalents reduced from ‚Çπ53,622 lakhs (Mar ‚Äô25) to ‚Çπ31,728 lakhs (Sep ‚Äô25).</li>
</ul>
<hr />
</div>
<div id="headwinds-challenges" class="section level6">
<h6>üå™Ô∏è <strong>2. Headwinds (Challenges)</strong></h6>
<div id="a.-supply-chain-disruption-major-one-off" class="section level9">
<p class="heading"><strong>a. Supply Chain Disruption (Major One-Off)</strong></p>
<ul>
<li><strong>Fire at CMO facility</strong> in Q1 led to <strong>~‚Çπ40 crores revenue loss in Q2 alone</strong>, cumulative impact <strong>‚Çπ70‚Äì75 crores over Q1‚ÄìQ2</strong>.</li>
<li>Affected key brands like <strong>Calpol</strong>, impacting availability in acute care segments.</li>
<li>CEO confirmed remediation is <strong>now complete</strong>, with supply normalized as of October 2025.</li>
</ul>
</div>
<div id="b.-gst-transitionary-impact" class="section level9">
<p class="heading"><strong>b. GST Transitionary Impact</strong></p>
<ul>
<li><strong>One-time GST implementation disruption</strong> cost <strong>~‚Çπ30‚Äì32 crores</strong> in lost sales.</li>
<li>Management expects normalization in Q3 and beyond.</li>
</ul>
</div>
<div id="c.-weak-external-market-growth" class="section level9">
<p class="heading"><strong>c.¬†Weak External Market Growth</strong></p>
<ul>
<li>Acute therapy market (anti-infectives, pain, dermatology) grew <strong>&lt;5%</strong>, below usual trends.</li>
<li>General Medicines business (80%+ of revenue) underperformed due to suppressed demand and supply issues.</li>
</ul>
</div>
<div id="d.-seasonal-product-mix-impact-on-margins" class="section level9">
<p class="heading"><strong>d.¬†Seasonal Product Mix Impact on Margins</strong></p>
<ul>
<li>Slight dip in gross margin due to <strong>monsoon-season low-margin product mix</strong>, though expected to improve over the year.</li>
</ul>
<hr />
</div>
</div>
<div id="tailwinds-growth-drivers" class="section level6">
<h6>‚úÖ <strong>3. Tailwinds (Growth Drivers)</strong></h6>
<div id="a.-resilient-profitability-and-margin-expansion" class="section level9">
<p class="heading"><strong>a. Resilient Profitability and Margin Expansion</strong></p>
<ul>
<li>Despite revenue impact, <strong>EBITDA margin improved to 34.4%</strong>, showing strong cost discipline.</li>
<li>Focus on:
<ul>
<li><strong>Gross margin expansion</strong></li>
<li><strong>Field cost productivity</strong></li>
<li><strong>Higher-margin specialty and vaccine products</strong></li>
</ul></li>
</ul>
</div>
<div id="b.-specialty-oncology-revival-new-growth-engine" class="section level9">
<p class="heading"><strong>b. Specialty &amp; Oncology Revival (New Growth Engine)</strong></p>
<ul>
<li>Launched <strong>Jemperli (Dostarlimab)</strong> for endometrial cancer and <strong>Zejula (Niraparib)</strong> for ovarian cancer in August 2025.</li>
<li>Symbolic <strong>re-entry into Oncology</strong> after long hiatus.</li>
<li>Already seeing <strong>early patient recruitment and momentum</strong>.</li>
<li>Supported by a dedicated team of <strong>~20 Key Account Managers (MRs)</strong>.</li>
<li>Targeting <strong>metropolitan and Tier-1 cancer centers</strong> across 20‚Äì25 cities.</li>
</ul>
</div>
<div id="c.-strong-vaccine-portfolio-growth" class="section level9">
<p class="heading"><strong>c.¬†Strong Vaccine Portfolio Growth</strong></p>
<ul>
<li><strong>Double-digit growth in both pediatric and adult (shingles) vaccines.</strong></li>
<li>Business <strong>stabilized and growing for 7‚Äì8 consecutive quarters</strong>, providing reliable top-line support.</li>
</ul>
</div>
<div id="d.-high-growth-platforms-scaling" class="section level9">
<p class="heading"><strong>d.¬†High-Growth Platforms Scaling</strong></p>
<ul>
<li><strong>Nucala and Trelegy Ellipta (respiratory) growing &gt;20% YoY</strong>.</li>
<li>Portfolio transformation toward <strong>innovative, high-category-growth products</strong> ongoing.</li>
</ul>
</div>
<div id="e.-broad-market-share-leadership" class="section level9">
<p class="heading"><strong>e. Broad Market Share Leadership</strong></p>
<ul>
<li>Maintained or gained market share in most brands despite weak market conditions.</li>
<li>EIs (index of brand performance) <strong>&gt;100</strong>, indicating outperformance vs.¬†market.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6>üìà <strong>4. Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="57%" />
</colgroup>
<thead>
<tr class="header">
<th>Area</th>
<th>Outlook</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>General Medicines</strong></td>
<td>Expected rebound in <strong>Q3‚ÄìQ4 FY26</strong> once supply issues are fully out of base effect and market normalizes.</td>
</tr>
<tr class="even">
<td><strong>Innovative Launches (Oncology &amp; Specialty)</strong></td>
<td>Emerging as sustained growth drivers. <strong>Future launches aligned with global timelines (no lag)</strong> due to India‚Äôs participation in <strong>16 ongoing global trials</strong>.</td>
</tr>
<tr class="odd">
<td><strong>Vaccines</strong></td>
<td><strong>Structural growth trend intact</strong> with strong brand equity and rising awareness.</td>
</tr>
<tr class="even">
<td><strong>Digital Investment</strong></td>
<td>Enhancing commercial engagement via digital ‚Äî supports long-term efficiency and reach.</td>
</tr>
<tr class="odd">
<td><strong>Growth Aspiration</strong></td>
<td><strong>Double-digit growth ambition remains intact</strong> for full-year and beyond once one-offs are washed out. Adjusted growth estimated at <strong>6‚Äì7%</strong> excluding fire and GST impact.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="key-risks-and-concerns" class="section level6">
<h6>‚ö†Ô∏è <strong>5. Key Risks and Concerns</strong></h6>
<table>
<colgroup>
<col width="35%" />
<col width="64%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Over-Reliance on CMOs</strong></td>
<td>Recurring issue (mentioned as 3rd in 10 years). Management asserts <strong>robust BCPs</strong>, but failure of a major CMO again could cause material disruption.</td>
</tr>
<tr class="even">
<td><strong>Imported Product Margins</strong></td>
<td><strong>Oncology and imported drugs have lower margins</strong> than core GM portfolio. Risk of <strong>margin dilution if low-margin sales grow faster</strong> than high-margin base.</td>
</tr>
<tr class="odd">
<td><strong>Mix Shift Risk</strong></td>
<td>As specialty and vaccines grow, <strong>revenue mix may shift to lower-margin products</strong>, requiring strong cost control and pricing discipline to sustain 34%+ EBITDA.</td>
</tr>
<tr class="even">
<td><strong>External Market Volatility</strong></td>
<td>Acute care drugs are <strong>seasonal and market-sensitive</strong>. Continued suppression in this ~80% of business can delay recovery.</td>
</tr>
<tr class="odd">
<td><strong>No Forward Guidance</strong></td>
<td>Company does not provide formal guidance, making financial forecasts less certain for investors.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="strategic-and-operational-confidence-indicators" class="section level6">
<h6>üü¢ <strong>6. Strategic and Operational Confidence Indicators</strong></h6>
<ul>
<li><strong>101 years of India operations</strong> ‚Äì strong legacy, trust, and patient brand recall.</li>
<li>New <strong>global leadership at parent GSK</strong> is focused on innovation ‚Äî <strong>India benefits</strong>.</li>
<li><strong>Sustainable margin model</strong> backed by gross margin focus and cost consciousness.</li>
<li><strong>Active R&amp;D pipeline alignment</strong> with global assets ‚Äî faster launches expected.</li>
<li><strong>Project Phoenix (patient assistance program)</strong> ensures affordability and access, reducing pricing resistance.</li>
</ul>
<hr />
</div>
<div id="summary-investment-theses" class="section level6">
<h6>üîö <strong>7. Summary: Investment Theses</strong></h6>
<div id="bull-case" class="section level9">
<p class="heading">‚úÖ <strong>Bull Case</strong></p>
<ul>
<li><strong>Post-CMO recovery + GST normalization ‚Üí volume rebound in H2.</strong></li>
<li><strong>Oncology &amp; specialty launches ‚Üí new long-term growth levers.</strong></li>
<li><strong>Vaccine growth momentum ‚Üí stable high-margin cash flow.</strong></li>
<li><strong>Margin resilience (34%+ EBITDA) ‚Üí strong profitability outlook.</strong></li>
<li><strong>Low valuation risk</strong> given track record of consistent returns.</li>
</ul>
</div>
<div id="bear-case" class="section level9">
<p class="heading">‚ùå <strong>Bear Case</strong></p>
<ul>
<li><strong>Repeat CMO failure ‚Üí further supply shocks.</strong></li>
<li><strong>Inability to scale oncology fast enough</strong> to offset GM volatility.</li>
<li><strong>Prolonged weak acute market growth</strong> ‚Üí revenue stagnation.</li>
<li><strong>Imported product sales increase mix shift ‚Üí margin pressure.</strong></li>
</ul>
<hr />
</div>
</div>
<div id="final-verdict-neutral-to-positive-buy-on-recovery" class="section level6">
<h6>üìä <strong>Final Verdict: NEUTRAL to POSITIVE (Buy on Recovery)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Category</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Fundamentals</strong></td>
<td>Solid (Profitability improving)</td>
</tr>
<tr class="even">
<td><strong>Growth Momentum</strong></td>
<td>Improving (once one-offs clear)</td>
</tr>
<tr class="odd">
<td><strong>Risk Profile</strong></td>
<td>Moderate (CMO, mix shift)</td>
</tr>
<tr class="even">
<td><strong>Valuation</strong></td>
<td>Not provided, but dividend track record supports stability</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üí° <strong>Recommendation Context</strong>:<br />
GLAXO is a <strong>mature pharma play undergoing transformation</strong>. Despite near-term headwinds, <strong>core profitability is robust</strong>, and <strong>new growth platforms are being successfully launched</strong>. The stock is suitable for <strong>long-term investors</strong> who can ride through supply chain volatility and benefit from gradual re-rating driven by innovation-led growth.</p>
</blockquote>
<blockquote>
<p><strong>Short-term</strong>: Wait for clearer signs of <strong>volume recovery in Q3</strong>.<br />
<strong>Mid-to-Long term</strong>: Accumulate on dips for exposure to <strong>India‚Äôs premium vaccine and specialty pharma story</strong>.</p>
</blockquote>
<hr />
</div>
<div id="key-numbers-to-watch-next-q3-fy26" class="section level6">
<h6>üìå Key Numbers to Watch Next (Q3 FY26)</h6>
<ol style="list-style-type: decimal">
<li><strong>Revenue Growth (YoY) ‚Äì</strong> Return to <strong>positive territory (&gt;5%)</strong>?</li>
<li><strong>Specialty &amp; Oncology Sales Ramp-up</strong> ‚Äì Is traction building?</li>
<li><strong>Gross and EBITDA Margins</strong> ‚Äì Can 34%+ EBITDA be sustained?</li>
<li><strong>Inventory Build-up</strong> ‚Äì Post-CMO recovery, is channel supply normal?</li>
<li><strong>Cash Flow from Operations</strong> ‚Äì Recovery after H1 dividend overhang.</li>
</ol>
<hr />
<p><strong>Disclaimer:</strong> This analysis is based on publicly disclosed information as of November 6, 2025. Forward-looking statements are subject to market, operational, and regulatory risks. Not investment advice.</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
